Josh Thomas Georgy/X
May 9, 2025, 14:19
Josh Thomas Georgy Highlights DESTINY-Breast11 Results in High-Risk HER2+ Early Breast Cancer
Josh Thomas Georgy, Assistant Professor of Medical Oncology, Associate Physician at Christian Medical College Vellore, shared a post on X:
“DESTINY-Breast11: T-DXd followed by THP significantly high pCR vs ddAC-THP in high-risk HER2+ EBC and better safety profile.
Neoadjuvant landscape shifting? Excited to see full efficacy + safety data in the paper.”
Ashish Singh, Professor, Medical Oncology, Christian Medical College Vellore India, added a comment:
“It’s like using a cruise missile for those 65% patients where the enemy can be defeated with a gun.. waiting for DB05 hope it turns out to be the nuke we need for patients at the highest risk of systemic relapse..”
More posts featuring Breast Cancer on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 9, 2025, 14:01
May 9, 2025, 13:49
May 9, 2025, 13:37